Balcom Alexandra insider trades
Balcom Alexandra has filed 31 Form 4s with the SEC that we hold, for Nuvalent, Inc. (NUVL) (Chief Financial Officer) and Crescent Biopharma, INC. (CBIO) (Director). Across all of them we count 0 purchases worth $0 and 81 sales worth $31.0M reported on Form 4. In the last 12 months: 0 purchases ($0) and 44 sales ($14.5M). The largest single trade was a sale of 30,000 shares of Nuvalent, Inc. worth $2.3M, dated 2023-12-18. The first filing on our record is dated 2022-01-05 and the latest 2026-07-15.
Nuvalent, Inc. (NUVL)
Chief Financial Officer · 29 filings · 81 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2023-07-31 | S, sale reported on Form 4 | 14,152 | $687.9K | 2023-08-01 |
| 2023-07-31 | S, sale reported on Form 4 | 10,848 | $536.9K | 2023-08-01 |
| 2023-12-18 | S, sale reported on Form 4 | 30,000 | $2.3M | 2023-12-20 |
| 2024-06-28 | S, sale reported on Form 4 | 572 | $43.9K | 2024-07-02 |
| 2024-06-28 | S, sale reported on Form 4 | 7,565 | $568.5K | 2024-07-02 |
| 2024-06-28 | S, sale reported on Form 4 | 1,863 | $141.9K | 2024-07-02 |
| 2024-07-31 | S, sale reported on Form 4 | 5,723 | $454.6K | 2024-08-02 |
| 2024-07-31 | S, sale reported on Form 4 | 896 | $69.0K | 2024-08-02 |
| 2024-07-31 | S, sale reported on Form 4 | 597 | $46.6K | 2024-08-02 |
| 2024-07-31 | S, sale reported on Form 4 | 1,649 | $132.5K | 2024-08-02 |
| 2024-07-31 | S, sale reported on Form 4 | 1,135 | $92.3K | 2024-08-02 |
| 2024-08-30 | S, sale reported on Form 4 | 4,481 | $378.9K | 2024-09-04 |
| 2024-08-30 | S, sale reported on Form 4 | 288 | $24.8K | 2024-09-04 |
| 2024-08-30 | S, sale reported on Form 4 | 5,231 | $438.7K | 2024-09-04 |
| 2024-09-30 | S, sale reported on Form 4 | 700 | $69.2K | 2024-10-02 |
| 2024-09-30 | S, sale reported on Form 4 | 2,963 | $301.9K | 2024-10-02 |
| 2024-09-30 | S, sale reported on Form 4 | 5,032 | $508.9K | 2024-10-02 |
| 2024-09-30 | S, sale reported on Form 4 | 1,305 | $130.6K | 2024-10-02 |
| 2024-10-31 | S, sale reported on Form 4 | 6,320 | $563.6K | 2024-11-04 |
| 2024-10-31 | S, sale reported on Form 4 | 1,600 | $144.5K | 2024-11-04 |
| 2024-10-31 | S, sale reported on Form 4 | 100 | $9.1K | 2024-11-04 |
| 2024-10-31 | S, sale reported on Form 4 | 1,980 | $174.7K | 2024-11-04 |
| 2024-11-29 | S, sale reported on Form 4 | 1,858 | $178.8K | 2024-12-03 |
| 2024-11-29 | S, sale reported on Form 4 | 8,142 | $779.1K | 2024-12-03 |
| 2025-01-06 | S, sale reported on Form 4 | 2,173 | $175.0K | 2025-01-08 |
| 2025-01-06 | S, sale reported on Form 4 | 691 | $54.8K | 2025-01-08 |
| 2025-01-06 | S, sale reported on Form 4 | 1,152 | $90.2K | 2025-01-08 |
| 2025-06-27 | S, sale reported on Form 4 | 20,000 | $1.6M | 2025-07-01 |
| 2025-07-15 | S, sale reported on Form 4 | 874 | $74.2K | 2025-07-17 |
| 2025-07-15 | S, sale reported on Form 4 | 54 | $4.6K | 2025-07-17 |
| 2025-07-15 | S, sale reported on Form 4 | 2,484 | $205.4K | 2025-07-17 |
| 2025-07-15 | S, sale reported on Form 4 | 1,888 | $158.3K | 2025-07-17 |
| 2025-07-16 | S, sale reported on Form 4 | 14,700 | $1.3M | 2025-07-17 |
| 2025-09-29 | S, sale reported on Form 4 | 7,588 | $645.1K | 2025-10-01 |
| 2025-09-30 | S, sale reported on Form 4 | 20,000 | $1.7M | 2025-10-01 |
| 2025-10-01 | S, sale reported on Form 4 | 970 | $83.8K | 2025-10-03 |
| 2025-10-01 | S, sale reported on Form 4 | 19,030 | $1.6M | 2025-10-03 |
| 2025-10-13 | S, sale reported on Form 4 | 12,266 | $1.1M | 2025-10-15 |
| 2025-10-13 | S, sale reported on Form 4 | 6,138 | $539.5K | 2025-10-15 |
| 2025-10-13 | S, sale reported on Form 4 | 1,596 | $142.4K | 2025-10-15 |
| 2025-10-14 | S, sale reported on Form 4 | 1,700 | $149.0K | 2025-10-15 |
| 2025-10-14 | S, sale reported on Form 4 | 5,820 | $504.2K | 2025-10-15 |
| 2025-10-14 | S, sale reported on Form 4 | 12,280 | $1.1M | 2025-10-15 |
| 2025-10-14 | S, sale reported on Form 4 | 200 | $17.8K | 2025-10-15 |
| 2025-10-15 | S, sale reported on Form 4 | 1,683 | $144.0K | 2025-10-17 |
| 2025-11-17 | S, sale reported on Form 4 | 5,055 | $522.0K | 2025-11-19 |
| 2025-11-17 | S, sale reported on Form 4 | 380 | $39.4K | 2025-11-19 |
| 2025-11-17 | S, sale reported on Form 4 | 3,194 | $326.2K | 2025-11-19 |
| 2025-11-17 | S, sale reported on Form 4 | 4,496 | $452.2K | 2025-11-19 |
| 2025-11-17 | S, sale reported on Form 4 | 3,266 | $310.7K | 2025-11-19 |
| 2025-11-17 | S, sale reported on Form 4 | 3,609 | $338.5K | 2025-11-19 |
| 2025-11-18 | S, sale reported on Form 4 | 220 | $22.8K | 2025-11-19 |
| 2025-11-18 | S, sale reported on Form 4 | 509 | $53.2K | 2025-11-19 |
| 2025-12-08 | S, sale reported on Form 4 | 6,984 | $770.4K | 2025-12-10 |
| 2025-12-08 | S, sale reported on Form 4 | 100 | $11.1K | 2025-12-10 |
| 2026-01-05 | S, sale reported on Form 4 | 1,929 | $189.0K | 2026-01-07 |
| 2026-01-05 | S, sale reported on Form 4 | 1,119 | $108.4K | 2026-01-07 |
| 2026-01-05 | S, sale reported on Form 4 | 317 | $31.2K | 2026-01-07 |
| 2026-01-05 | S, sale reported on Form 4 | 871 | $83.7K | 2026-01-07 |
| 2026-01-06 | S, sale reported on Form 4 | 225 | $22.1K | 2026-01-07 |
| 2026-01-06 | S, sale reported on Form 4 | 1,635 | $159.1K | 2026-01-07 |
| 2026-01-06 | S, sale reported on Form 4 | 1,321 | $127.8K | 2026-01-07 |
| 2026-03-24 | S, sale reported on Form 4 | 7,671 | $735.5K | 2026-03-26 |
| 2026-03-24 | S, sale reported on Form 4 | 2,599 | $247.0K | 2026-03-26 |
| 2026-03-24 | S, sale reported on Form 4 | 1,160 | $111.9K | 2026-03-26 |
| 2026-03-25 | S, sale reported on Form 4 | 13,700 | $1.4M | 2026-03-26 |
| 2026-04-01 | S, sale reported on Form 4 | 2,469 | $262.2K | 2026-04-03 |
| 2026-04-01 | S, sale reported on Form 4 | 5,417 | $570.4K | 2026-04-03 |
| 2026-04-01 | S, sale reported on Form 4 | 3,544 | $370.0K | 2026-04-03 |
| 2026-05-01 | S, sale reported on Form 4 | 124 | $12.4K | 2026-05-05 |
| 2026-05-01 | S, sale reported on Form 4 | 7,434 | $738.1K | 2026-05-05 |
| 2026-05-01 | S, sale reported on Form 4 | 3,872 | $381.1K | 2026-05-05 |
| 2026-06-01 | S, sale reported on Form 4 | 900 | $87.9K | 2026-06-03 |
| 2026-06-01 | S, sale reported on Form 4 | 1,200 | $118.3K | 2026-06-03 |
| 2026-06-01 | S, sale reported on Form 4 | 960 | $91.1K | 2026-06-03 |
| 2026-06-01 | S, sale reported on Form 4 | 2,170 | $208.3K | 2026-06-03 |
| 2026-06-01 | S, sale reported on Form 4 | 200 | $20.8K | 2026-06-03 |
| 2026-06-01 | S, sale reported on Form 4 | 3,133 | $312.9K | 2026-06-03 |
| 2026-06-01 | S, sale reported on Form 4 | 2,588 | $260.5K | 2026-06-03 |
| 2026-06-01 | S, sale reported on Form 4 | 279 | $28.4K | 2026-06-03 |
| 2026-07-01 | S, sale reported on Form 4 | 11,430 | $1.4M | 2026-07-06 |
Crescent Biopharma, INC. (CBIO)
Director · 2 filings · 0 purchases and sales
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Source
Counted from the Form 4 filings this reporting owner (SEC CIK 1862147) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms